Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lets keep at it guys / gals lol but really lets move this baby were it needs to be
lets slap that ask come on lets get it
lets all hit it together
LKSD WATCH FOR NEWS ,PR TO DROP AND WE ARE GONE THESE ARE THE LAST OF THE CHEAPIES HERE
LKSD IS GONNA BLOW WAY PAST A DOLLAR ITS COMING I HOPE EVERYONE IS LOADED
lets but that 10 cent mark today
iam looking foward to it go lksd
I plan on loading some more but help me understand what u just said here lol
I BELIVE WE GET SOME SORT OF NEWS NEXT WEEK AND IMAGINE IF WE GET PRE MARKET NEWS MONDAY BOOOOOOM
YOU ARE 1000000000 PERCENT RIGHT PEOPLE ARE GONNA WISH THEY WOULD HAVE LOADED THESE CHEAP SHARES UP ILL BE HERE FOR THE FIRE WORKS
LKSD THESE PRICES ARE GIFTS IAM LOADED WHEN A PR OR NEWS DROPS WE COULD DOLLARS HIT WITHIN MOMENTS OF NEWS ,PR ,ECT
gooooood morning lets get it
LETS GET IT
LOOKING GOOD HERE
LOOKING GOOD HERE TODAY
post rs play
also watching for more news
watching for the dip
will be adding
BOOM ANOTHER TWEET JUST NOW I BET WE GET A MASSIVE PR AFTER MARKET CLOSES
'DERBYBLOOD EVERYONE BLOCK THIS GUY HE IS HERE TO CERATE PANIC AND GET YOUR SHARES
yep we have a gapper boooooooom klets see that 5 cents today
yep its gonna be massive
no not old news do some diging lol were good but i hope people are looking and diging here its amazing we got a winner here
shorts gonna burn today lol go nspx
5 plus coming today this is massive
lets stay focused here we got a massive stock here lets see a run to 4 to 5 cents tommorow
looking for a gap up tomorrow and run to 4 to 5 cents tomorrow
BOOOOOOOOOOOOOOOM https://phytonbiotech.com/covid19-update/
BOOOMMMMMMMMMMM Phyton Biotech COVID-19 Update
March 19th, 2020
BOOOM HERE U GO MARCH 19 TH 2020 https://phytonbiotech.com/covid19-update/
EVERYONE HERE U DO REALIZE THAT THEY CAN ANOUNCE THE BUY OUT ANY TIME TODAY TOM .ECT BUT WE HAVE A MONSTER HERE
I AGREE HOLD TIGHT FOR THE REAL MONEY PEOPLE
NSPX BOOOOOOOOOOOOOOM BABY
THEY BOUGHT TO EVERYONE KNOWS THIS IS THE BEST PLAY AND ITS HEADING STRAIGHT TO DOLLAR LAND
NSPX IS MUCH BIGGER THAN ANYONE CAN IMAGINE IF A PR DROPS WE WILL SEE DOLLARS THE CHASE WILL BE ON CALL ME CRAZY I DONT CARE IVE DONE DD ALL DAY ON THIS STOCK IF U DONT OWN SHARES U CAN WATCH THE REST OF US GET PAID
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug remdesivir to accelerate its emergency use for multiple severely ill patients.
The drugmaker said it’s switching to “expanded access” from a “compassionate use” program under which remdesivir was given to more than 1,000 Covid-19 patients.
“With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time,” Daniel O’Day, Gilead’s chairman and chief executive officer, said in an open letter sent by email Saturday. “While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people.
A World Health Organization panel said in January that remdesivir was considered to be the most promising therapeutic candidate based on its broad antiviral spectrum, and existing data based on human and animal studies. The medication was developed initially for Ebola and studied in patients in Eastern Congo.
Multiple clinical trials are investigating the drug’s effects in Covid-19 patients in China and elsewhere. Initial results may be reported in the coming weeks, O’Day said.
If it is approved, the Foster City, California-based company “will work to ensure affordability and access so that remdesivir is available to patients with the greatest need,” he said.
“The urgency comes from knowing the desperate need among patients and the lack of any approved treatment,” O’Day said. “The responsibility is to ensure that remdesivir, an investigational medicine, is effective and safe before it is distributed for use worldwide.”
— With assistance by Nathan Crooks
(Adds WHO panel’s determination in fourth paragraph.)
Have a confidential tip for our reporters?
GET IN TOUCH
Before it's here, it's on the Bloomberg Terminal.
LEARN MORE
by Taboola
Sponsored Links
From The Web
I DONT THINK MANY EVEN SEE THE VALUE HERE I SMELL A MASSIVE BUY OUT COMING THIS STOCK HAS DOLLARS ALL OVER IT I HOPE THAT U GUYS LIKE MONEY ANYTHING UNDER 5 CENTS WILL SEEM TO BE GOLD IMO THIS IS MASSIVE
With the recent rise of news surrounding COVID-19 treatments and vaccines, companies working in the space such as Gilead Sciences has seen their stock's share price rise nearly 30% since January, 21, 2020. Adding over $20 Billion to their market cap.
This leaves good reason to speculate that Inspyr Therapeutics can prove to be a pivotal player in the race to provide treatments to 100s of millions of people that may require treatment just in the United States alone over the coming months (or maybe years). Their technology and long list of patents may leverage their value to secure partner deal with a top biotech company like Gilead, Roche, and others currently working on treatments and vaccines, or increasing the probability for an outright acquisition of Inspyr.
Also, to note, the intellectual property (IP) supporting Inspyr Therapeutics (formerly known as GenSpera) technology was developed over 15 years at Johns Hopkins University and the University of Copenhagen with over $15 million in scientific grants from the National Cancer Institute, the U.S. Department of Defense, and the U.S. National Institutes of Health, among others. Their IP portfolio contains several issued patents and along with several pending patent applications. As reported by Crunchbase, Inspyr Therapeutics has raised $22.8 million.
According to Inspyr's latest share price and filings, they have 11,383,983 outstanding shares and a market cap of about $30,000. For a company that has such promising therapies for cancer and potentially the treatment of COVID-19 symptoms, one would think this company is grossly undervalued.
You can learn more about Inspyr Therapeutics here:
THEY ARE STILL COMING UP WITH A CURE FOR CANCER THAT IS MASSIVE ITS SELF AND THIS STOCK IS SO UNDERVALUED IT HAS SO MUCH ROOM